Financial Architects, Inc Alaunos Therapeutics, Inc. Transaction History

Financial Architects, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $1,194 - $1,860	-300 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$2.0 - $4.4 $600 - $1,320	300 New	300 $1,000
Q1 2019 May 03, 2019	SELL	$2.0 - $4.4 $600 - $1,320	-300 Closed	0 $0
Q4 2018 Feb 01, 2019	SELL	$1.61 - $3.62 $161 - $362	-100 Reduced 25.0%	300 $1,000
Q2 2018 Aug 03, 2018	SELL	$3.02 - $4.94 $2,114 - $3,458	-700 Reduced 63.64%	400 $1,000
Q3 2017 Nov 01, 2017	BUY	$4.99 - $6.57 $5,489 - $7,227	1,100	1,100 $7,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $493M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.